IP Library Granted Patent US 7,276,619
Granted Patent B2
US 7,276,619 · App. 10/801,741 · Granted Oct 2, 2007

Vitreoretinal silicone tamponades made by supercritical fluid extraction

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,276,619
App. No.
10/801,741
Granted
Oct 2, 2007
Kind
B2
Abstract

A process for the purification of a silicone oil or fluid using neat supercritical carbon dioxide or a supercritical carbon dioxide mixture extraction to produce vitreoretinal silicone tamponades. The subject process is an economical, highly effective, reproducible, contaminant-free method by which unreacted relatively low molecular weight cyclic siloxanes and oligomers are removed from relatively high molecular weight silicone oil or fluid.

Claims (17)

1. A method of using a tamponade in an ophthalmic surgical procedure comprising:

creating an incision into a posterior chamber of an eye; and

filling said posterior chamber of the eye with said tamponade consisting essentially of a silicone oil that was purified by supereritical carbon dioxide extraction to remove cyclic and oligomeric impurities.

2. The process of claim 1 wherein said extraction is conducted at a pressure of approximately 3000 psi, and a temperature of approximately 55 degrees Celsius.

3. The process of claim 1 wherein said extraction is conducted at a carbon dioxide flow rate of approximately 20 to 26 gm/minute and a flow time of approximately 90 minutes.

4. A method of using a tamponade in an ophthalmic surgical procedure comprising:

creating an incision into a posterior chamber of an eye; and

filling said posterior chamber of the eye with said tamponade consisting essentially of a silicone oil that was purified with a mixture comprising carbon dioxide under supercritical extraction conditions to remove cyclic and oligomeric impurities.

5. The process of claim 4 wherein said extraction is conducted at a pressure of approximately 3000 psi, and a temperature of approximately 55 degrees Celsius.

6. The process of claim 4 wherein said extraction is conducted at a carbon dioxide mixture flow rate of approximately 20 to 26 gm/minute and a flow time of approximately 90 minutes.

7. The process of claim 4 wherein said carbon dioxide mixture comprises approximately 90 percent carbon dioxide and approximately 10 percent acetone.

8. The process of claim 4 wherein said carbon dioxide mixture comprises carbon dioxide and a modifier.

9. The process of claim 4 wherein said carbon dioxide mixture comprises carbon dioxide and acetone or acetonitrile.

10. The process of claim 4 wherein said carbon dioxide mixture comprises carbon dioxide and methanol.

11. The process of claim 4 wherein said carbon dioxide mixture comprises carbon dioxide and isopropanol.

12. The process of claim 4 wherein said carbon dioxide mixture comprises approximately 90 percent carbon dioxide and approximately 10 percent methanol.

13. The process of claim 4 wherein said carbon dioxide mixture comprises approximately 90 percent carbon dioxide and approximately 10 percent isopropanol.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Sep 4, 2013
From: BAUSCH & LOMB INCORPORATED
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 031156/0508 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2013
From: CITIBANK N.A., AS ADMINISTRATIVE AGENT
To: WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.); BAUSCH & LOMB INCORPORATED; ISTA PHARMACEUTICALS
Reel/Frame 030995/0444 →